Download PDF
Thromb Haemost 2018; 118(04): 791-797
DOI: 10.1055/s-0038-1636543
Atherosclerosis and Ischaemic Disease
Schattauer GmbH Stuttgart

Angiopoietin-2 and Survival in Peripheral Artery Disease Patients

Clemens Höbaus
1   Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Gerfried Pesau
1   Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Carsten Thilo Herz
1   Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
2   Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
,
Thomas Wrba
3   IT4Science, IT-Systems and Communications, Medical University of Vienna, Vienna, Austria
,
Renate Koppensteiner
1   Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Gerit-Holger Schernthaner
1   Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
› Author Affiliations Funding Funding was provided by Medical University Vienna, Vienna, Austria.
Further Information

Publication History

18 October 2017

15 January 2018

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Abstract

Survival of peripheral arterial disease (PAD) patients increased over the last decade due to increased use of secondary preventive medication and rapid revascularization of PAD patients. Angiogenetic markers such as vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2) and its receptor Tie-2 might be useful markers to assess the residual risk for mortality in PAD patients. The aim of this study was to evaluate angiogenetic markers for the prediction of mortality in a PAD cohort. For this purpose, 366 patients (mean age: 69 ± 10 years) with PAD Fontaine stage I or II were included and followed up over a 5-year study period. Serum Ang-2, Tie-2 and VEGF levels were measured by bead-based multiplex assay. All-cause mortality and major cardiovascular events (MACE) including all-cause death, non-fatal stroke and non-fatal myocardial infarction were analysed by Kaplan–Meier and Cox regression analyses after 5 years. Ang-2 was associated with Tie-2 (R = 0.151, p = 0.006) and VEGF levels (R = 0.160, p = 0.002). However, only Ang-2 was linked to all all-cause mortality in PAD patients (hazard ratio [HR]: 1.55 [1.23–2.15], p = 0.008) even after adjustment for age and gender, haemoglobin A1c, low-density lipoprotein cholesterol, systolic blood pressure and glomerular filtration rate (HR: 1.44 [1.03–2.00], p = 0.032). Furthermore, an association of Ang-2 and MACE in PAD patients (HR: 1.36 (1.03–1.78), p = 0.028) was found. This result implies that Ang-2 might be used as an additional marker to stratify PAD patients to predict poor mid-term life expectancy.

Keywords

angiopoietin-2 - Tie-2 - vascular endothelial growth factor - mortality - peripheral arterial disease - atherosclerosis

Authors' Contributions

C.H. performed the literature search; designed the study; performed the Ang-2, Tie-2 and VEGF measurements; conducted the statistical analyses and interpretation of the results; and drafted the manuscript. G.P. contributed to the data collection of the VMC cohort and measurement of Ang-2, Tie-2 and VEGF. C.T.H. revised the statistical analyses, performed interpretation of the results and contributed to the drafting of the manuscript. T.W. contributed to the data collection, data coordination and data management. R.K. participated in the interpretation of the results and revised the manuscript. G.H.S. designed the VMC study cohort, directed and performed the statistical analyses, interpretation of the results and revised the manuscript. All authors read and approved the final manuscript.


 

  • References

  • 1 Faxon DP, Fuster V, Libby P. , et al; American Heart Association. Atherosclerotic vascular disease conference: Writing Group III: pathophysiology. Circulation 2004; 109 (21) 2617-2625
    CrossrefPubMedGoogle Scholar
  • 2 Norgren L, Hiatt WR, Dormandy JA. , et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) S1-S75
    CrossrefPubMedGoogle Scholar
  • 3 Espinola-Klein C, Rupprecht HJ, Bickel C. , et al; AtheroGene Investigators. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation 2008; 118 (09) 961-967
    CrossrefPubMedGoogle Scholar
  • 4 Wickström JE, Laivuori M, Aro E. , et al. Toe pressure and toe brachial index are predictive of cardiovascular mortality, overall mortality, and amputation free survival in patients with peripheral artery disease. Eur J Vasc Endovasc Surg 2017; 53 (05) 696-703
    CrossrefPubMedGoogle Scholar
  • 5 Subherwal S, Patel MR, Kober L. , et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 2012; 126 (11) 1345-1354
    CrossrefPubMedGoogle Scholar
  • 6 Gasse C, Jacobsen J, Larsen AC. , et al. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg 2008; 35 (01) 51-58
    CrossrefPubMedGoogle Scholar
  • 7 Blinc A, Kozak M, Šabovič M. , et al. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease. Int Angiol 2017; 36 (03) 216-227
    PubMedGoogle Scholar
  • 8 Hussain MA, Al-Omran M, Mamdani M. , et al. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg 2016; 151 (08) 742-750
    CrossrefPubMedGoogle Scholar
  • 9 Höbaus C, Herz CT, Obendorf F. , et al. Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Ann Med 2017; 49 (04) 291-298
    CrossrefPubMedGoogle Scholar
  • 10 Aboyans V, Ricco JB, Bartelink MEL. , et al; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39 (09) 763-816
    CrossrefPubMedGoogle Scholar
  • 11 Gerhard-Herman MD, Gornik HL, Barrett C. , et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135 (12) e686-e725
    CrossrefPubMedGoogle Scholar
  • 12 Roller RE, Renner W, Dorr A, Pilger E, Schnedl WJ. Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease. Thromb Haemost 2001; 85 (02) 368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Moore MA, Hattori K, Heissig B. , et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001; 938: 36-45 , discussion 45–47
    PubMedGoogle Scholar
  • 14 Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407 (6801): 242-248
    CrossrefPubMedGoogle Scholar
  • 15 Wu H, Shou X, Liang L, Wang C, Yao X, Cheng G. Correlation between plasma angiopoietin-1, angiopoietin-2 and matrix metalloproteinase-2 in coronary heart disease. Arch Med Sci 2016; 12 (06) 1214-1219
    PubMedGoogle Scholar
  • 16 Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110 (16) 2355-2360
    CrossrefPubMedGoogle Scholar
  • 17 Pöss J, Ukena C, Kindermann I. , et al. Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol 2015; 104 (05) 380-387
    CrossrefPubMedGoogle Scholar
  • 18 David S, John SG, Jefferies HJ. , et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 2012; 27 (05) 1867-1872
    CrossrefPubMedGoogle Scholar
  • 19 Golledge J, Clancy P, Yeap BB, Hankey GJ, Norman PE. Increased serum angiopoietin-2 is associated with abdominal aortic aneurysm prevalence and cardiovascular mortality in older men. Int J Cardiol 2013; 167 (04) 1159-1163
    CrossrefPubMedGoogle Scholar
  • 20 World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ . Accessed August 21, 2017
    PubMedGoogle Scholar
  • 21 European Parliament C. Directive. 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32001L0020:EN:NOT . Accessed February 1, 2017
    PubMedGoogle Scholar
  • 22 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedGoogle Scholar
  • 23 Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27 (12) 2918-2924
    CrossrefPubMedGoogle Scholar
  • 24 Takahashi Y, Satoh M, Tabuchi T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels 2012; 27 (04) 337-343
    CrossrefPubMedGoogle Scholar
  • 25 Lorbeer R, Baumeister SE, Dörr M. , et al. Angiopoietin-2, its soluble receptor Tie-2 and subclinical cardiovascular disease in a population-based sample. Heart 2015; 101 (03) 178-184
    CrossrefPubMedGoogle Scholar
  • 26 Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 2008; 52 (05) 387-393
    CrossrefPubMedGoogle Scholar
  • 27 Tressel SL, Kim H, Ni CW. , et al. Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol 2008; 28 (11) 1989-1995
    CrossrefPubMedGoogle Scholar
  • 28 Lorbeer R, Baumeister SE, Dörr M. , et al. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail 2013; 15 (12) 1327-1334
    CrossrefPubMedGoogle Scholar
  • 29 Tsai YC, Lee CS, Chiu YW. , et al. Angiopoietin-2 as a prognostic biomarker of major adverse cardiovascular events and all-cause mortality in chronic kidney disease. PLoS One 2015; 10 (08) e0135181
    CrossrefPubMedGoogle Scholar
  • 30 Meng R, Pei Z, Chen B. , et al. Age-related change of serum angiogenic factor levels in patients with coronary artery disease. Acta Cardiol 2009; 64 (06) 735-740
    CrossrefPubMedGoogle Scholar
  • 31 Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180 (01) 113-118
    CrossrefPubMedGoogle Scholar
  • 32 Korff T, Ernst E, Nobiling R. , et al. Angiopoietin-1 mediates inhibition of hypertension-induced release of angiopoietin-2 from endothelial cells. Cardiovasc Res 2012; 94 (03) 510-518
    CrossrefPubMedGoogle Scholar
  • 33 David S, Kümpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009; 27 (08) 1641-1647
    CrossrefPubMedGoogle Scholar
  • 34 Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008; 40 (03) 215-222
    CrossrefPubMedGoogle Scholar
  • 35 Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83 (08) 852-859
    CrossrefPubMedGoogle Scholar